Publication2020
A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia
The record
- Type
- Publication
- Date
- 1 June 2020
- Level
- National
- Journal
- British Journal of Clinical Pharmacology
- Volume
- 86
- Issue
- 6
- Pages
- 1081-1088
- Published
- 1 June 2020
- DOI
- 10.1111/bcp.14216
- Scopus ID
- 85079733299
- ISSN
- 03065251
- Authors
- 10
- Open access
- No
- Citations
- 34
- International co-authorship
- No
- Co-author countries
- IN
Classification
Every label below carries the reasoning it was assigned on, the confidence band it was assigned in, and what produced it. The rubric is published.
UN Sustainable Development Goals
3 Ensure healthy lives and promote well-being for all at all ages
Comparative analysis of generic L-asparaginase formulation quality and activity in pediatric acute lymphoblastic leukemia treatment reveals significant variability in therapeutic efficacy.
- High confidence
- The subject matter is a strong and direct inference from the record type, the funding or organising body, or the programme context, even where the title alone is thin. Example: an ICMR-funded project against SDG 3, on the strength of the agency.
- Judged
- Judged against the published classification rubric, under the rubric and prompt versions recorded with the run that produced it.
- Produced by
- claude-haiku-4-5-20251001, under kortex-publication-v1
5 Achieve gender equality and empower all women and girls
Equitable access to quality cancer therapeutics for pediatric populations addresses healthcare equity in oncology treatment.
- Moderate confidence
- The alignment is plausible and defensible but rests on an assumption a reasonable reviewer could decline. Published, and surfaced in the review queue for a human to confirm or override.
- Produced by
- claude-haiku-4-5-20251001, under kortex-publication-v1
Viksit Bharat @2047
vb-1.2 Health and well-being
Quality pediatric cancer treatment access supports health equity and well-being advancement.
- Produced by
- claude-haiku-4-5-20251001, under kortex-publication-v1
Each label above carries the instrument and the version that produced it. How each classification is reached.
Evidence
Kortex hosts no documents. Evidence is an outbound link to the authority that holds it.
No outbound evidence link is recorded for this activity. The record below states which source it came from and when it was last read.
Provenance
Which source system this record came from, how many source rows were resolved into it, and when each was last read.
- Source rows resolved into this record
- 1
Each record carries the date Kortex last read it from its source system. That is a freshness date and not a verification: Kortex records what its sources say and when it read them, and it does not check those statements against any external authority. No claim on this site is described as verified, because none is.
Citing this record
This URL is stable. A record’s permalink is frozen when it is published and is not regenerated if its title is later corrected.
KIIT Deemed to be University. “A comparison of asparaginase activity in generic formulations of E.coli derived L- asparaginase: In-vitro study and retrospective analysis of asparaginase monitoring in pediatric patients with leukemia”. Kortex.